Schedule an Appointment

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Windsor Botanical Therapeutics Inc.

Location: Toronto, Ontario

Sector: Life Science

 

Add to Shortlist
Express Interest

Windsor Botanical Therapeutics Inc. is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB. This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.

Business Documents

MG cp Summary
  • If clinical testing results allow DRE-W to make cancer treatment claims, then DRE-W will stand out as a unique product in the natural health care product market – Currently available natural healthcare products can not make any claims regarding use as a cancer treatment.
  • Each batch of DRE-W produced by WBTI is quality controlled to ensure its ability to kill cancer cells. Studies conducted by WBTI provided the basis for a validated quantitative method of quality control- Studies conducted by WBTI showed that the effectiveness of homemade and commercially produced dandelion root extract vary widely or are non-existent.
  • Our research indicates that DRE-W is non-toxic: the Stage 1 Clinical trial will officially confirm this and the Stage 2 Trial should confirm that DRE-W improves patients’ well-being and reverses the progress of their disease Chemotherapy is toxic and can cause nausea, loss of appetite, loss of hair, discomfort, and a weakening of the body’s immune system.
  • WBTI owns a patent for the process to produce quality controlled DRE-W- Homemade and commercially available dandelion root extract either does not kill cancer cells or has no consistency in doing so. WBTI has spent the last 6 years researching and developing protocols to create effective DRE-W and only WBTI has the patent for its manufacturing process.

WBTI is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB.  This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.

Joseph Elliot, Chief Executive Officer, Director

 Dr. Elliot is founding President  & CEO of Windsor Botanical Therapeutics Inc. a developer and marketer of a breakthrough natural therapy for terminal cancer patients.

He is also Principal at Biopharm Management Inc. (BMI) a Toronto, Canada based firm providing short and long term management services to the biopharmaceutical industry. For the past 27 years Dr. Elliot has been a serial entrepreneur and former venture capitalist.

Dr. Elliot is a hands-on manager with skills and experience in all facets of the biopharmaceutical business including raising capital, financing, licensing, team building, drug development, manufacturing, regulatory affairs (FDA, Health Canada and BfArM).  He has broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases.

Through BMI, Dr. Elliot is currently Managing Director of ERC USA, the North American subsidiary of ERC Belgium, a break-through developer of therapeutic cancer vaccines.

In the past 15 years, Dr. Elliot has raised over $30 million for a number of companies in which he played a leading management role including the founding and growing several biotech companies. These include President & CEO of Receptor Therapeutics Inc., President & CEO of LymphoSign Inc., Vice President & General Manager Operations for MDS Proteomics Inc.; Chief Operating Officer for MDS Ocata Inc.; Interim Chief Operating Officer of Exogen Neurosciences Inc. He is the founding President and Chairman of PhageTech Inc. of Montreal, Quebec which had a successful IPO under the name Targanta Therapeutics Corporation. He was also initial CEO of Cytochroma Inc., (which was subsequently acquired by OPKO in 2013). He is also a past director of Nexia Biotechnologies Inc. of Montreal, Quebec, and BIOSTAR Inc. of Saskatoon, Saskatchewan.  From 1996 to 1999 he was a Vice President (Venture Capital) with MDS Capital Corp. specializing in early stage biotechnology investments.